Alessandra Holzem

Alessandra Holzem

Auto-generated profile, based on publicly available information

Alessandra Holzem

Department of Medicine III, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2022 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
RFRuth Flümann
Ruth Flümann
JHJulia Hansen
Julia Hansen
BPBenedikt W. Pelzer
Benedikt W. Pelzer
PNPascal Nieper
Pascal Nieper
TLTim Lohmann
Tim Lohmann
GKGero Knittel
Gero Knittel
Genomic profiling revealed the identity of at least 5 subtypes of diffuse large B-cell lymphoma (DLBCL), including the MCD/C5 cluster characterized by aberrations in MYD88, BCL2, PRDM1, and/or SPIB. We generated mouse models harboring B cell–specific Prdm1 or Spib aberrations on the background of oncogenic Myd88 and Bcl2 lesions. We deployed whole-exome sequencing, transcriptome, flow-cytometry, and mass cytometry analyses to demonstrate that Prdm1- or Spib-altered lymphomas display molecular features consistent with prememory B cells and light-zone B cells, whereas lymphomas lacking these alterations were enriched for late light-zone and plasmablast-associated gene sets. Consistent with the phenotypic evidence for increased B cell receptor signaling activity in Prdm1-altered lymphomas, we demonstrate that combined BTK/BCL2 inhibition displays therapeutic activity in mice and in five of six relapsed/refractory DLBCL patients. Moreover, Prdm1-altered lymphomas were immunogenic upon transplantation into immuno-competent hosts, displayed an actionable PD-L1 surface expression, and were sensitive to antimurine-CD19-CAR-T cell therapy, in vivo. Significance: Relapsed/refractory DLBCL remains a major medical challenge, and most of these patients succumb to their disease. Here, we generated mouse models, faithfully recapitulating the biology of MYD88-driven human DLBCL. These models revealed robust preclinical activity of combined BTK/BCL2 inhibition. We confirmed activity of this regimen in pretreated non–GCB-DLBCL patients. See related commentary by Leveille et al., p. 8. This article is highlighted in the In This Issue feature, p. 1

16 July 2025 in Infection
Verified
Journal Article
Open access
PDF file
AHA. Holzem
A. Holzem
JSJannik Stemler
Jannik Stemler
SBS. Böhm
S. Böhm
HGH. Gruell
H. Gruell
AZA. Zeuzem
A. Zeuzem
F(For The Infectious Diseases Working Party (Agiho) Of The German Society Of Hematology And Medical Oncology (Dgho)
For The Infectious Diseases Working Party (Agiho) Of The German Society Of Hematology And Medical Oncology (Dgho)
Purpose: In 2024, human parvovirus B19 (PB19V) infections have increased in Germany and globally. It is an infection associated with a broad spectrum of clinical manifestations. To raise awareness, we present representative cases and virological data from different specialties across three German university hospitals. Methods: Following a nationwide survey by the AGIHO in March 2024 indicating increased PB19V infections, we conducted a retrospective, multi-center descriptive study across Munich, Cologne, and Magdeburg. Anonymized clinical and virological data from 2022 to 2024 were collected, including patient demographics, underlying diseases, and diagnostic findings. Acute PB19V infection was defined by real-time quantitative PCR-based detection of PB19V DNA in any specimen. Results: Clinical manifestations of acute PB19V infections can range from severe anemia and pancytopenia in hematologic patients, to fetal hydrops in pregnant women, and systemic inflammatory symptoms in patients with chronic conditions. In 2024, the Max von Pettenkofer Institute in Munich conducted 936 PB19V PCR tests. A marked increase in positive cases was observed in early 2024, with positivity rates of 16% in Q1 and 18.2% in Q2, compared to an annual positivity rate of 2.3% in 2023. Similar trends were seen at the University Hospitals Cologne and Magdeburg. Most infections were acute with high viral loads. Most cases originated from pediatric, gynecologic, and hematologic departments, highlighting particularly vulnerable patient populations. Conclusions: This resurgence in symptomatic PB19V infections, likely driven by pandemic-related shifts in immunity and exposure, underscores the need for heightened clinical awareness, early testing in high-risk populations, and sustained surveillance to anticipate future outbreaks.

27 February 2026 in Blood Advances
Verified
Journal Article
Open access
GMGiulia Magno
Giulia Magno
KRKai Rejeski
Kai Rejeski
GRGiulia Rappa
Giulia Rappa
Sophia StockSophia Stock
Sophia Stock
AHAlessandra Holzem
Alessandra Holzem
Marion SubkleweMarion Subklewe
Marion Subklewe
T-cell–redirecting bispecific antibodies (bsAb) offer a novel therapeutic approach for relapsed/refractory large B-cell lymphoma (R/R LBCL). However, predictive biomarkers are needed to identify patients most likely to respond. As both bsAbs and chimeric antigen receptor (CAR) T cells represent T-cell–based therapies, we hypothesized that the established CAR-HEMATOTOX (HT) and InflaMix models—reflecting the degree of systemic inflammation—could be of prognostic utility for bsAb therapy. We applied both scores to a multicenter international cohort of 174 patients with R/R LBCL treated with bsAbs across 15 sites. Patients with a high HT score (≥3, 35%) displayed inferior median progression-free (PFS; 1.4 vs 7.4 months; P< .0001) and overall survival (OS; 2.0 vs 21.7 months; P< .0001) compared with patients with a low HT score. When applying the InflaMix score, 49% of the patients were assigned to the inflammatory cluster, translating into a significantly shorter median PFS (1.9 vs 17.8 months; P< .0001) and OS (4.1 vs 21.7 months; P< .0001). In a multivariable Cox regression analysis accounting for various prognostic factors, HT and InflaMix remained independent adverse risk factors for both PFS and OS. Patients presenting with both elevated HT score and the inflammatory signature showed markedly shorter OS and PFS compared with patients deemed low-risk by either one of the scores. In the CAR-pretreated subcohort, the combination of early CAR T-cell relapse (≤3 months) and elevated inflammation led to particularly detrimental outcomes. Overall, these data highlight the prognostic utility of baseline inflammatory markers in identifying patients who may benefit from combinatorial strategies alongside bsAb.